Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

NCT02204904 · clinicaltrials.gov ↗

TERMINATED

Status

59

Enrollment

INDUSTRY

Sponsor class

Stopped Sufficient enrollment for Month 24 safety and efficacy endpoints

Conditions

X-Linked Adrenoleukodystrophy (X-ALD)
Cerebral Adrenoleukodystrophy (CALD)
Adrenoleukodystrophy (ALD)

Interventions

GENETIC: Allo-HSCT

Sponsor

Genetix Biotherapeutics Inc.